Results 11 to 20 of about 5,472 (197)

Prolonged Terlipressin Therapy as a Bridge to Curative TIPS for HRS-AKI in a Nontransplant Candidate. [PDF]

Case Reports Hepatol
Hepatorenal syndrome–acute kidney injury (HRS–AKI) is a severe complication of advanced cirrhosis with high mortality and limited treatment options. Terlipressin is currently the only FDA‐approved therapy for HRS, though recurrence is common upon discontinuation in patients without access to liver transplantation.
Reidy D, Jesudian A, Salerno D, Lucero C.   +3 more
europepmc   +2 more sources

Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. [PDF]

Liver Int
ABSTRACT Background & Aims Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of decompensated cirrhosis. The US Food and Drug Administration approved terlipressin use for HRS‐AKI based on the CONFIRM study, which demonstrated a significant improvement in HRS reversal with terlipressin versus placebo.
Rockey DC, Gordon F, Thuluvath PJ, Victor D, Kemmer N, Cardoza S, Jamil K, Frederick RT.   +7 more
europepmc   +2 more sources

Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. [PDF]

Aliment Pharmacol Ther
In a pooled analysis, bradycardia was observed in 6% of terlipressin‐treated patients but rarely required a dose interruption or reduction. Arrhythmia serious adverse event incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin ...
Bajaj JS, Kwo P, Pappas SC, O'Leary JG, Jamil K, Cardoza S, Wong F.   +6 more
europepmc   +2 more sources

Challenges in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes. [PDF]

JGH Open
ABSTRACT Background Treatments for hepatorenal syndrome with acute kidney injury (HRS‐AKI) that are not FDA‐approved have been widely used in the United States (US) with variable outcomes. This study describes the practice patterns, outcomes, and healthcare utilization around vasopressor use before terlipressin approval in 2022. Methods A retrospective
Sanyal AJ, Reddy KR, Brown KA, Landis CS, Cullaro G, Huang X, Kelkar SS, Raina R, Corman S, Kebede N, Edmundson P, Jamil K, Allegretti AS.   +12 more
europepmc   +2 more sources

Improvement of gut-vascular barrier by terlipressin reduces bacterial translocation and remote organ injuries in gut-derived sepsis

Frontiers in Pharmacology, 2022
Gut-vascular barrier (GVB) serves as the last barrier to limit the migration of intestinal toxins into the blood circulation. The efficacy of terlipressin (a vasopressin V1 receptor agonist) in reducing GVB and multiple organ damage in gut-derived sepsis
Zenan Chang, Zenan Chang, Yinan Zhang, Ming Lin, Shihong Wen, Hanjin Lai, Yaqing Zhan, Xiufen Zhu, Zhikun Huang, Xuyu Zhang, Zimeng Liu   +10 more
doaj   +1 more source

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies [PDF]

, 2017
Background The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available.
Araya, V., Boyer, T. D., Escalante, S., Frederick, R. T., Jamil, K., Pappas, S. C., Reddy, K. R., Rossaro, L., Sanyal, A. J., Teuber, P., Vargas, H. E., Wong, F.   +11 more
core   +2 more sources

Addition of terlipressin to norepinephrine in septic shock and effect of renal perfusion: a pilot study

Renal Failure, 2022
Purpose Terlipressin improves renal function in patients with septic shock. However, the mechanism remains unclear. Here, we aimed to evaluate the effects of terlipressin on renal perfusion in patients with septic shock.Materials and Methods This pilot ...
Jinlong Wang, Mengjuan Shi, Lili Huang, Qing Li, Shanshan Meng, Jingyuan Xu, Ming Xue, Jianfeng Xie, Songqiao Liu, Yingzi Huang   +9 more
doaj   +1 more source

A rare and threatening complication in a cirrhotic patient [PDF]

, 2018
info:eu-repo/semantics ...
Anapaz, V, Branco, J, Reis, J, Santos, L
core   +1 more source

Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial

Critical Care Explorations, 2023
IMPORTANCE AND OBJECTIVES:. This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting. DESIGN:.
Constantine J. Karvellas, MD, Ram Subramanian, MD, Jody C. Olson, MD, Khurram Jamil, MD   +3 more
doaj   +1 more source

Terlipressin or norepinephrine in septic shock: do we have the answer? [PDF]

, 2019
Comment on Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial.
Russell, James A., Williams, Mark D.
core   +1 more source